Our Innovations

A composition including a C terminal region having residues corresponding to a peptide identified by PDB ID: 1RG3; an N terminal region having residues corresponding to a peptide identified by PDB ID: 1RG4; and a disulfide linkage between the residues near the C terminal region and the N terminal region.

The invention is based, in part, on the discovery of a novel cell-based immunotherapy that can recapitulate neutrophil functions in neutropenic individuals afflicted with a microbial infection. The therapeutic methods of the invention are broadly applicable to treat any infection in a neutropenic individual, including infections caused by bacteria, fungi, protozoa, and viruses. The methods of the invention represent a practical, rapid cell-based immunotherapy for refractory infections comprising compositions of activated, irradiated HL-60 cells.

Treating or inhibiting an ischemic condition affecting the skeletal muscle comprising administering an agent having a property to inhibit an activity or a protein expression of myostatin or growth differentiation factor 8 (GDF-8) according to a regimen to treat or inhibit the ischemic condition. Treating or inhibiting an ischemic condition affecting the skeletal muscle including administering an effective amount of a thiazolidenedione or other PPAR gamma agonist at a dosage that do not exert glycemic control or induce overweight.

The invention provide isolated peptides, protides and conjugates having novel peptide sequences which are able to induce antimicrobial, anti-cancer, anti-inflammatory, anti-proliferative or programmed cell death activity. The invention also provides a method of inducing programmed cell death in a cell by contacting the cell with an isolated peptide, protide or conjugate described herein. In some aspects, the method can be used in the diagnosis, prevention, or treatment of a disease, such as an infection, cancer, autoimmune disease, or inflammatory disease.

The invention provides a composition including at least one iron chelating compound and at least one antifungal agent. The composition can include the iron chelating compounds deferiprone or deferasirox. An antifungal agent included in the composition can include a polyene antifungal agent, an azole antifungal agent or an echinocandin antifungal agent. The invention also provides a method of treating or preventing a fungal condition.

The present invention provides therapeutic compositions and methods for treating and preventing fungal disease or conditions including mucormycosis. The therapeutic methods and compositions of the invention include vaccine compositions having an FTR polypeptide or an antigenic fragment of the polypeptide; a vector including a nucleotide sequence that is substantially complimentary to at least 18 contiguous nucleotides of FTR sequence; an antisense; a small interfering RNA or an antibody inhibitor of FTR. The vaccine compositions of the invention can further include an adjuvant.

The present invention provides novel kinocidin peptides comprising a C-terminal portion of a kinocidin, wherein the C-terminal portion encompasses an α-helical secondary structure and further displays antimicrobial activity. The kinocidin peptides of the invention are derived from and correspond to a C-terminal portion of a kinocidin that includes a γ_KC core and that can be a CXC, CC, or C class chemokine.

This invention relates generally to antimicrobial agents, and more specifically pertains to peptides useful as antimicrobial agents for the prevention and treatment of infections caused by organisms, such as bacteria and fungi, many of which are resistant to conventional antibiotics

A method of inhibiting myostatin expression or activity to increase muscle mass. Methods for locally inhibiting myostatin expression or activity to reduce fibrosis are provided. The method introduces a nucleotide sequence into a vector wherein the nucleotide sequence is expressed as a shRNA having a property to inhibit myostatin expression. The vector including the sequence may be delivered to a mammalian tissue. An electrical pulse may be applied across a point of delivery.

The invention provided Mucorales CotH polypeptides and encoding nucleic acid molecules. The Mucorales CotH polypeptides and encoding nucleic acids can be advantageously used to diagnose, treat or prevent fungal conditions, in particular mucormycosis.

This invention provides novel compositions and methods for the specific and/or preferential delivery of an effector (e.g. a drug or label) to an epithelial cell (e.g. a pulmonary epithelium). The compositions comprise an adipocyte differentiation-related protein (ADRP) attached to an effector thereby forming a chimeric moiety. The chimeric moiety is preferentially delivered to epithelial cells.

This invention is directed to multifunctional, context-activated protides that have two or more effectors with individually distinct biological functions and one or more corresponding activator sites that can each initiate or amplify the biological function of one or more effectors upon context-activation. The context-activated protides of the invention are useful in the diagnosis, prophylaxis, and therapy of a broad range of pathological conditions.

As this application has not been published yet by the patent office, details are only available under a confidentiality agreement.

As this application has not been published yet by the patent office, details are only available under a confidentiality agreement.

As this application has not been published yet by the patent office, details are only available under a confidentiality agreement.

As this application has not been published yet by the patent office, details are only available under a confidentiality agreement.

A therapeutic pharmaceutical composition for the treatment of respiratory disease is disclosed, including particularly Respiratory Distress Syndrome (RDS). The composition is comprised of a synthetic dimer of an N-terminal fragment of Surfactant Protein B (SP-B) that advantageously mimics the functional activity of native human Surfactant Protein B, and to therapeutic methods of administration of such pharmaceutical compositions.

Antigen specific immune tolerance is induced in a mammalian host by administration of a toleragen in combination with a regimen of immunosuppression. The methods optionally include a preceding conditioning period, where immunosuppressive agents are administered in the absence of the toleragen. After the tolerizing regimen, the host is withdrawn from the suppressive agents, but is able to maintain specific immune tolerance to the immunogenic epitopes present on the toleragen.

The present invention relates to synthetic lung surfactant compositions that include a novel surface active peptide and a phospholipid, including phospholipase-resistant phospho-glycerol derivatives, phospholipase-resistant phospho-choline derivatives, naturally occurring phospholipids, or a combination thereof. Uses of the surfactant compositions of the present invention to treat endogenous surfactant dysfunctional or deficient lung tissue and to deliver therapeutic agents are also disclosed.

As this application has not been published yet by the patent office, details are only available under a confidentiality agreement.

As this application has not been published yet by the patent office, details are only available under a confidentiality agreement.

Malaria, a mosquito-borne parasitic disease, affects 3.3 billion people worldwide where 214 million cases were reported in 2015 alone. With a 90% mortality rate in Africa and increasing rates of infections, an alternative method of  treatment is needed. Our inventor has designed a potent peptide that exhibits antiparasitic effects on one of the major strains responsible for Malaria infection, p. falciparum. This strain is also responsible for the most severe and complicated cases associated with high mortality. The invention has shown potent efficacy in the treatment of p.

As this application has not been published yet by the patent office, details are only available under a confidentiality agreement.

The present invention provides therapeutic compositions and methods for treating and preventing fungal disease or conditions including mucormycosis. The therapeutic methods and compositions of the invention include antibody, antibody fragment, siRNA and vaccine compositions having or directed against a GRP78 polypeptide or an antigenic fragment of the polypeptide.

The present invention provides vaccine and pharmaceutical compositions for treating or preventing bacterial infections. The vaccine compositions of the invention include a carbapenemase such as a serine carbapenemase, a metallo-β-lactamase, or an immunogenic fragment thereof. The pharmaceutical compositions include an anti-carbapenemase antibody or fragment thereof. Also provided are methods for treating and preventing a bacterial infection using the vaccine and pharmaceutical compositions of the invention.

The invention provides a method of killing an infectious microbe by administering an effective amount of transferrin to an individual having a microbial infection, wherein the transferrin has microbicidal activity, thereby reducing survival of the infectious microbe in the individual.

This invention provides compositions for inducing an immune response in a vertebrate host against a protozoan parasite. In certain embodiments the composition comprises a protozoan parasite comprising a psoralen-modified DNA, whereby said protozoan parasite is killed but metabolically active (KBMA); and optionally a Toll-like receptor agonist.

A novel peptide-based prevention and treatment of invasive aspergillosis (fungal).

Embodiments disclosed herein relate to compositions comprising extracellular thaumatin domain proteins, or portions thereof (e.g., CalA polypeptides, or portions thereof), and compositions comprising binding agents (e.g., antibodies, fragments thereof, and the like) that bind specifically to CalA polypeptides, and methods of using the same for preventing or treating a fungal infection.

The invention provides a method for preventing or treating a disease caused by an extracellular microorganism. Said method comprising systemically administering to a subject in need thereof a prophylactically or therapeutically effective amount of a salicylic acid (SAL) or a SAL analog. The extracellular microorganism can be of the bacterial genus Staphylococcus. The extracellular microorganism can be a strain that is resistant to at least one antibiotic.

Described herein are methods of protecting germ cells in a subject from cell death induced by a chemotherapeutic agent by, in part, administering a composition comprising one or more humanin polypeptides to the subject. Also described herein are methods of inhibiting a reduction or decrease in fertility in a subject wherein the reduction or decrease in fertility is due to a chemotherapeutic agent.

Described herein are methods of protecting germ cells in a subject from cell death induced by a chemotherapeutic agent by, in part, administering a composition comprising one or more humanin polypeptides to the subject. Also described herein are methods of inhibiting a reduction or decrease in fertility in a subject wherein the reduction or decrease in fertility is due to a chemotherapeutic agent.

A method of reducing, eliminating, and/or reversing pulmonary tissue damage characterized by smoke-induced pulmonary alveolar trans-differentiation of lipofibroblasts to myofibroblasts in utero in a developing fetus carried by a pregnant mammal. Said method comprising a PPAR gamma (PPARγ) agonist to said pregnant mammal in an amount sufficient to reduce, eliminate, or reverse said transdifferentiation.

Methods to treat and prevent peritoneal injury using JAK inhibitors. The invention provides, in certain embodiments, a method of preventing and/or treating peritoneal injury and/or diminished function by administering an effective amount of one or more inhibitors of JAK. The invention also provides a pharmaceutical composition including a JAK inhibitor for the treatment of peritoneal injury and/or diminished function. In another aspect, the invention provides a method of detecting an indicator of peritoneal injury.

The present methods and compositions are of use for treatment of conditions involving fibrosis, such as Peyronie's disease plaque, penile corporal fibrosis, penile veno-occlusive dysfunction, Dupuytren's disease nodules, vaginal fibrosis, clitoral fibrosis, female sexual arousal disorder, abnormal wound healing, keloid formation, general fibrosis of the kidney, bladder, prostate, skin, liver, lung, heart, intestines or any other localized or generalized fibrotic condition, vascular fibrosis, arterial intima hyperplasia, atherosclerosis, arteriosclerosis, restenosis, cardiac hypertrophy, hyp

A composition including an effective amount of a treatment agent to inhibit tumor growth in a mammal by manipulating a prostaglandin D2 biosynthetic pathway. A method comprising introducing an effective amount of a treatment agent to a mammal to inhibit tumor growth by manipulating a prostaglandin D2 biosynthetic pathway while at the same time reducing production of other forms of prostaglandins that may produce ill effects, such as prostaglandin E2.

Provided herein are compositions, methods and uses of humanin or a humanin analog in treating a subject with humanin to protect white blood cells from suppression or cell death induced by an autoimmune, anti-tumor or anti-cancer therapeutic agent.

The invention is a method of reducing, decreasing or inhibiting cardiotoxicity in a subject from an anti-cancer therapeutic agent suppression or death, where cardiotoxicity is induced, promoted, increased stimulated by anti-cancer treatment in conjunction with humanin, or a humanin analog to protect, reduce, decrease or inhibit cardiotoxicity.

As this application has not been published yet by the patent office, details are only available under a confidentiality agreement.

The invention provides, in certain embodiments, a method of assaying an indicator of, and treating, renal injury or renal disease. The method entails assaying a urine sample for periostin, wherein the presence of periostin at an elevated level indicates the presence and/or degree of renal injury or renal disease. The method also involves prescribing, initiating, or altering prophylaxis or therapy for renal injury or renal disease. Also provided, are methods of determining progression of these conditions, as well as methods of determining subjects' response to treatment.

The invention provides, in certain embodiments, a method of detecting an indicator of renal injury or renal disease. The method entails assaying a urine sample for hematopoietic growth factor inducible neurokinin-1 (HGFIN), wherein the presence of HGFIN at an elevated level indicates the presence and/or degree of renal injury or renal disease, and/or the rate of loss of renal function. In other embodiments, the invention provides a method of detecting an indicator of systemic inflammation.

Methods of inhibiting lipofibroblast to myofibroblast transdifferentiation in a mammal are disclosed comprising administering a PPAR gamma ligand when said mammal is exposed to a hyperoxic condition.

Described herein are methods for determining the overall survival of maintenance hemodialysis patients. The methods include measuring low density lipoprotein (LDL) particle size and subfraction concentrations as prognostic tools for early mortality risk detection. For example, the presence of increased very small LDL concentration or decreased LDL particle size in blood-serum serves as a useful means for prognostic risk assessment and monitoring.

This invention pertains to the discovery that Parathyroid Hormone-related Protein (PTHrP) can be detect and/or stage, and/or treat chronic lung diseases. In particular, it was discovered that PTHrP levels in broncho-alveolar lavage are indicative of lung “health” and “disease,” and can be used to predict lung disease in patients at risk of chronic lung disease and/or to evaluate the efficacy of a ventilation regime.

As this application has not been published yet by the patent office, details are only available under a confidentiality agreement.

As this application has not been published yet by the patent office, details are only available under a confidentiality agreement.

An apparatus including a main processing unit. The apparatus further including a precordial patch coupled to the main processing unit, the precordial patch having a plurality of sensors for detecting heart sounds and cardiac electrical signals (ECG). The apparatus further including a probe coupled to the main processing unit, the probe having a sensor for detecting oxygen saturation of blood circulating through a human.

An apparatus including a chest strip including a plurality of precordial leads positioned to correspond with desired lead placement for an electrocardiogram; and a plurality of limb leads coupled to the chest strip.

Apparatus configured to detect congenital heart disease (CHD) in newborns may comprise a body with a cavity configured to receive a hand or foot of a newborn. Sensor pairs of the apparatus may be configured scan such that the best signals can be selected, which can accommodate for movements of the newborn and/or facilitate impartialness as to which body part is inserted in the apparatus. Positions of the sensor pairs may be adjusted to ensure contact with the newborn's skin. A disposable cover may protect the newborn's skin from contacting the apparatus.

An apparatus may be configured for documenting a code blue scenario when adhered to the chest of a subject undergoing resuscitation by sensing and transmitting information associated with the code blue scenario. Such information may include one or more of vital signs of the subject during resuscitation, information associated with chest movements of the subject during resuscitation, and audio information from an environment of the subject during resuscitation.

A method including placing a portion of a foot of a newborn in a device, the device including a light emitter and a corresponding receiver coupled on opposite sides of the device, the device further including a processor for processing data from the light emitter and receiver; and determining a presence of congenital heart disease.

A method for monitoring blood/tissue gases, blood pH, and other elements of blood and tissue chemistry is described that uses a sensor tip that is placed adjacent to the conjunctiva of a patient to be monitored. Monitors and sensor using optical fiber sensors for performing the monitoring are also described.

Exemplary implementations may provide objective, continuous, and clinically useful assessment of asthma control in subjects including young children using a device that is compact, non-intrusive, and simple. The device may include a water-resistant, flexible patch that can be comfortably worn for two weeks or more. In some implementations, the patch may resemble a Band-Aid® that is placed on the supra-sternal notch. The device may record respiratory sounds that can be analyzed to identify coughing and wheezing episodes.

A novel wearable device (12 lead ECG) to monitor heart condition at home. 

An airway management device including a tubular member dimensioned for introducing air into a trachea of a mammal, the tubular member having a proximal portion, a distal portion, and a middle portion between the proximal portion and the distal portion. The tubular member is dimensioned for positioning of the proximal portion in an oral cavity of a mammal, the middle portion in an oropharynx of the mammal and the distal portion in an esophagus of the mammal. An inflatable oral cavity balloon is positioned at the proximal portion and dimensioned to occlude the oral cavity.

An apparatus including an accelerometer and a microphone contained in a housing that can be placed on a chest of an individual, the accelerometer configured to detect chest motion and microphone to detect respiratory sounds during at least one of inspiration and expiration. A method including placing such an apparatus on a chest of a subject. A method of monitoring an intubation including simultaneously assessing chest movement and air movement sounds in the airway and lungs; and indicating the status of the intubation based on the assessing.

A fluid delivery and airway management device including a tubular member dimensioned for introducing a fluid into a trachea of a mammal, the tubular member having a proximal portion, a distal portion, and a middle portion between the proximal portion and the distal portion. The tubular member is dimensioned for positioning of the proximal portion in an oral cavity of a mammal, the middle portion in an oropharynx of the mammal and the distal portion in an esophagus of the mammal.

A novel medical device that can be used to treat children under emergency situations. An overinflation and/or overventilation device includes a body configured to attach to a resuscitation interface and a gas source, a subject metric input component disposed at the body, the subject metric input component configured to receive input specifying a metric associated with a resuscitation subject; and a volume control mechanism disposed within the body, the volume control mechanism configured to control a volume of gas provided by the gas source during a manual resuscitation that is communicated

A system is described for measuring amniotic fluid volume and/or assessing fetal weight. The system includes an ultrasound apparatus to scan a pregnant uterus and to generate data representative of a three-dimensional construction of the scanned uterus, and a processor to compute a volume of amniotic fluid or weight of fetal tissue based on the three-dimensional construction of the scanned uterus. Also a method of computing a volume of amniotic fluid and/or a weight of fetal tissue.

A treadmill test protocol is provided having a linearly increasing work rate profile achieved by increasing walking speed while simultaneously increasing treadmill inclination. Specifically, according to the protocol it is possible to use a test subject's projected maximum end-test work rate to calculate a treadmill test protocol having a linear increase in walking speed and simultaneous curvilinear increase in treadmill grade so that when the test subject is tested according to the calculated protocol, the test result yields a work rate and oxygen uptake response with a linear slope.

A method and system for detection of respiratory variation in pulse oximetry are provided. In one embodiment, the method includes detecting a pattern consistent with a respiratory cycle of a waveform representing cardiac oscillations and identifying an abnormality based on the pattern. The method further includes triggering an alarm in response to identifying an abnormality. A system is further provided including a database and a module.

A method and system for automatically detecting pulsus paradoxus. In one embodiment, the method includes automatically detecting pulsus paradoxus based upon a consideration of a blood pressure component, an audio component indicative of Korotkoff sounds and a respiratory component. The system includes a plurality of input modules for determining a blood pressure, a Korotkoff sound and a respiration of a subject.

Quantitative computed tomography (QCT) is the currently used technique for three-dimensional BMD measurement. Since bone density can be measured in trabecular and cortical bone compartments, thoracic QCT is an important technique for estimating and monitoring bone strength, especially bone mineral density (BMD) measurement. There is a significant positive association between BMD values obtained from the thoracic and lumbar spinal vertebrae.

Embodiments include methods, devices, software, and systems for identifying a person based on relatively permanent pigmented or vascular skin mark (RPPVSM) patterns in images. Locations of RPPVSMs in different images of people are point matched, and a correspondence probability that the point matched RPPVSMs are from different people is calculated. Other embodiments are also described and claimed.

The present invention is directed to a method of determining vein patterns from a color image for personal identification, the method comprising forming a counterpart of the color image by applying a functional relationship obtained from optimization on the color image, wherein the counterpart of the color image comprises the vein patterns. An apparatus for determining vein patterns from a color image is also disclosed.

A method including isotope labeling of a newly synthesized protein in a sufficient quantity such that a newly synthesized protein spectra and the pre-existing protein spectra are sufficiently separated. A further method including determining a ratio of a new and a pre-existing protein from mass spectra obtained by using mass spectrometry. In this method a resultant spectrum may be presented as integrated peak heights for a corresponding mass to charge ratio in the “centroid” mode.